Actively Recruiting
Phase 3 Study Evaluating Safety and Efficacy of JNT-517 Compared to Placebo in Treating Phenylketonuria with Two Treatment Periods
Led by Otsuka Pharmaceutical Development & Commercialization, Inc. · Updated on 2026-10-21
120
Participants Needed
26
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, effectiveness, and how the body processes a drug called JNT-517 in children, adolescents, and adults who have phenylketonuria, a condition affecting phenylalanine levels in the body. This Phase 3 study aims to understand the impact of JNT-517 on managing phenylalanine levels and related symptoms in people with this condition. Participants will be randomly assigned to receive either JNT-517 or a matching placebo orally twice daily for an initial 6-week period. After this, eligible participants will continue with JNT-517 treatment for an additional 46 weeks, with dosing based on age. This study includes two treatment periods a blinded 6-week phase followed by an open-label 46-week phase where all participants receive JNT-517. During the study, participants will undergo regular assessments including measurement of plasma phenylalanine levels at various timepoints, evaluations of attention-related symptoms, dietary intake monitoring, and safety evaluations. Researchers will track changes in phenylalanine from baseline through week 6 and week 52, as well as treatment-emergent adverse events. The total participation duration includes 6 weeks of blinded treatment plus 46 weeks of open-label treatment, with ongoing monitoring throughout.
CONDITIONS
Brief Title
A Study of JNT-517 in Participants With Phenylketonuria (PKU)
Research Team
O
Otsuka Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here